Lumos Pharma — NewLink Genetics — FY2016 Earnings Presentation
7 slides from Lumos Pharma's earnings presentation, Feb 28, 2017
Slide 1: Fourth Quarter and Year-End 2016 Financial Results
NewLink Genetics Corporation Nasdaq: NLNK February 28, 2017 Fourth Quarter and Year-End 2016 Financial Results
Slide 2: Agenda
Agenda 2 Introduction Jack Henneman, Executive Vice President & CFO 2017 Ongoing Priorities Charles J. Link, Jr., M.D., Chairman, CEO & CSO Clinical Updates / Anticipated News Flow Nicholas N. Vahanian, M.D., President & CMO Fourth Quarter and Year-End 2016 Financial Results Mr. Henneman
Slide 3: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements, w
Slide 4: NewLink Genetics – 2016 Takeaways
4 NewLink Genetics – 2016 Takeaways The IDO pathway is central to immune escape in many types of cancers The IDO pathway is becoming increasingly validated as an immuno-oncology target Two product candidates that target the IDO pathway, with distinct mechanisms of action GDC-0919; Targets th
Slide 5: IDO Pathway Inhibitor Clinical Development
IDO Pathway Inhibitor Clinical Development 5 AGENT INDICATION REGIMEN PHASE 1 PHASE 2 PHASE 3 Indoximod Advanced Melanoma Indoximod + PD-1 inhibitors or ipilimumab Metastatic Pancreatic Cancer Indoximod + gemcitabine and nab-paclitaxel Metastatic Breast Cancer Indoximod + taxane Malignant Brain Tumo
Slide 6: YE Cash and Equivalents and Key Financial Metrics
Fourth Quarter and Year-End 2016 Financial Results YE Cash and Equivalents $131.5 million Debt ~$0.5 million YE 2017 Cash (Projected) ~$75 million Quarterly Negative Cash-Flow ~$13 million Shares Outstanding 29.2 million Market Capitalization $435 million* Headcount 122 6 *As of February 21, 2017 Ma
Slide 7: Q & A
7 Q & A